Most material SEC filings — July 27, 2026

argenx BV agreed to acquire all outstanding shares of Forte Biosciences, Inc. for $77.00 per share in an all-cash tender offer, valuing the company at approximately $1.58 billion (20.49 million shares × $77). The merger agreement was executed July 26, 2026, with the Offer to commence within 10 business days. The transaction is structured as a two-step: tender offer followed by merger under DGCL Section 251(h), requiring no stockholder vote post-acceptance. Board unanimously approved; Supporting Stockholders committed to tender.

Clean Energy Technologies, Inc. (via subsidiary Herbert YF Global Holding Limited) entered a consulting agreement with Linkage International Limited dated July 1, 2025 to explore acquiring Ortus Climate Mitigation LLC's Italian operations. The deal structure requires a HKD 25,000,000 (~$3.2M) refundable deposit (4.5% of EUR 60M target) and HKD 5,000,000 consulting fee (1%). Amendment No. 1 (effective November 17, 2025) secures the deposit refundability with 715,447 shares of CETY common stock purchased by the Consultant on May 6, 2025; if CETY does not pursue the transaction, those shares revert to CETY for cancellation.

Camp4 Therapeutics received regulatory clearance from Australia's Therapeutic Goods Administration and local Human Research Ethics Committee to initiate a Phase 1/2 clinical trial of CMP-002 for SYNGAP1-related disorder. This milestone triggers eligibility for up to $50 million in additional gross proceeds (via 32,721,172 common shares or pre-funded warrants) from a September 2025 Securities Purchase Agreement, with closing expected within five business days. Committed investors include Coastlands Capital, Janus Henderson Investors, Balyasny Asset Management, Vivo Capital, 5AM Ventures, Adage Capital Management, Trails Edge Capital Partners, and CURE SYNGAP1.

MapLight announced positive topline results from the Phase 2 ZEPHYR trial (N=307) of ML-007C-MA in schizophrenia on July 27, 2026. The 210/3 mg BID dose met the primary endpoint with PANSS total score improvement of 4.5 points vs. placebo (effect size 0.37, p=0.015; effect size 0.50 in completers analysis, p=0.002). The drug also showed significant cognitive improvement (effect size 0.51, p=0.041) on a prespecified secondary endpoint in cognitively impaired patients, with favorable tolerability (no serious drug-related adverse events, 19.9% discontinuation rate, low GI discontinuations). The company plans to initiate a confirmatory Phase 3 pivotal trial (ZEPHYR-2) and engage with FDA at an End-of-Phase 2 meeting.

Neumora reported favorable repeat toxicology results for NMRA-215 (NLRP3 inhibitor for obesity/cardiometabolic disease) after a prior 13-week rat study showed unexpected adverse findings in 5 of 142 animals. A repeat study in 162 rats found no such adverse findings; the company attributes prior findings to audit discrepancies unrelated to the drug. Plans to submit IND application Q4 2026 and initiate Phase 1 by year-end 2026.

Baker Hughes completed its all-cash acquisition of Chart Industries (NYSE: GTLS) in July 2026. The company simultaneously announced the sale of Waygate Technologies to Hexon for ~$1.45 billion. IET segment orders doubled year-over-year to $7.1 billion in Q2 2026; management raised full-year IET order guidance and increased Horizon 2 (2026-2028) IET orders outlook to >$45 billion. RPO reached record $40.1 billion, with IET RPO at $37.1 billion.

AT&T signed an agreement to expand deployment of D-Wave's annealing quantum computing technology for network optimization. In early testing, AT&T reduced processing time for a network optimization workload from ~1 hour to <15 seconds. AT&T plans broader deployment across outage detection, technician routing, network planning, and traffic management, and is evaluating D-Wave's gate-model systems for quantum security and communications applications. No financial terms, contract value, or duration disclosed.

Expand Energy Corporation agreed to acquire Twin Eagle Holdings, a private natural gas marketing company, from Five Point Infrastructure for $1.25 billion in an all-cash/credit facility transaction expected to close Q3 2026. Twin Eagle markets 5 Bcf/d of natural gas, serves 1,000+ customers across U.S. and Canada, and is projected to contribute >$200M annual EBITDA with $150M annual synergies by year-end 2028. The combined entity will market ~14 Bcf/d and reach ~90% of North American natural gas demand; Expand raised its marketing/commercial strategy free cash flow target to $750M/year (50% increase from prior guidance).

Ensign Group reported Q2 2026 diluted EPS of $1.68 (GAAP) and $1.92 (adjusted), up 16.7% and 20.8% YoY respectively. The company raised full-year 2026 earnings guidance to $7.75–$7.85 per share (from $7.48–$7.62) and revenue guidance to $5.87–$5.92B (from $5.81–$5.86B). In Q2, Ensign added 20 new operations via acquisition, bringing total portfolio to 398 facilities across 17 states. Standard Bearer segment posted $44.1M rental revenue (+40.2% YoY) with $24.7M FFO (+34.6% YoY). Same-facility occupancy reached 84.1%, skilled mix revenue grew 10.1%, and Medicare revenue improved 9.8%—all YoY comparisons.

HBT Financial reported Q2 2026 net income of $27.8M ($0.76/share) versus $11.2M in Q1 2026, with adjusted net income of $28.5M ($0.78/share). The company completed its acquisition of CNB Bank Shares, Inc. on March 1, 2026 (acquiring ~$1.5B in deposits). Net interest margin expanded 12 basis points to 4.32% (tax-equivalent 4.38%); nonperforming assets fell to 0.15% of assets. The Board raised the quarterly cash dividend from $0.23 to $0.25 per share. Total assets grew to $6.7B; total loans to $4.75B; deposits to $5.76B. Acquisition-related expenses totaled $0.3M in Q2 (down from $15.7M in Q1), and management expects no material acquisition expenses in subsequent quarters.